Log In Sign up
The largest database of trusted experimental protocols
> Disorders > Neoplastic Process > Multiple Myeloma

Multiple Myeloma

Multiple myeloma is a type of blood cancer that affects plasma cells, a type of white blood cell.
It is characterized by the uncontrolled growth and accumulation of abnormal plasma cells in the bone marrow, which can lead to a variety of complications, including bone pain, fractures, and kidney problems.
PubCompare.ai is an AI-driven platform that can help researchers optimize their multiple myeloma research by providing powerful comparison tools to locate the best protocols from literature, preprints, and patents.
Leverage this platform to identify the most effective treatments and discover the future of protocol optimization today.

Most cited protocols related to «Multiple Myeloma»

1
Multilevel Cytokine Profiling of Common Diseases
Cited 26 times
From 169 patients, a total of 191 samples, for either one or two of four possible sample types (plasma, saliva, serum and urine) were purchased from Bioreclamation Inc (Hicksville, NY). All blood specimens were collected at clinical locations using standard vacutainer-type blood collection tubes and processed to plasma or serum by the vendor. The samples were aliquoted and stored frozen at −80 °C for single use. Bioreclamation Inc. collects every sample under IRB approved protocols, where ethical guidelines are followed to protect patient confidentiality and safety. Each sample has the patients consent for use in a wide range of research including the development of commercial products or services.
Patients were classified as either normal or as having one of seven possible disease states (COPD, Mononucleosis, Myeloma, Psoriasis, Rheumatoid Arthritis, and Type 2 Diabetes). Patient personal record and medical history were blinded and their sample identification was randomized prior to analysis. Samples were analysed across three 96-well plates, labelled here as Plate = (plate1, plate2, plate3), for the presences of 37 analytes (April, Baff, CD163, CD30, Chitinase, gp130, IFN-a2, IFN-b, IFN-g, IL-10, IL-11, IL-12p40, IL-12p70, IL-19, IL-2, IL-20, IL-22, IL-26, IL-27, IL-28, IL-29, IL-32, IL-34, IL-35, IL-6RA, IL-8, Light, MMP-1, MMP-2, MMP-3, OCN, OPN, Pentraxin, TNFR1, TNFR2, TSLP, and Tweak). The actual number of patients associations between sample types, conditions and plates are given in Supplementary Table S1. Note, the 16 mononucleosis patients across plasma and serum are paired, as is the 6 myeloma patients across plasma and serum. All other patient groups represent different patients. All samples were diluted 4-fold with sample diluent prior to data acquisition.
The fluorescence responses and concentrations of analytes were obtained using a Bio-Plex Pro™ Human Inflammation Panel 37-Plex assay kit with magnetic beads (171AL1001M, Bio-Rad, Hercules, California, USA) and analysed with a Luminex100 system and the accompanying Bio-Plex ManagerTM Software 6.1(Bio-Rad, Hercules, California, USA).
The concentration values and detection limits were determined from standard curves generated from each kit’s standards using the Bio-Plex Software ManagerTM weighted 5PL curve fitting procedure. To maximize the number of concentrations values available for analysis we included the Bio-Plex extrapolated values. Therefore, the definition of out-of-range here, and unless otherwise stated, refers to concentration values that cannot be obtained from the 5PL logistic curve; that is beyond extrapolation.
All statistical analysis was performed using R version 3.1.0 (2014-04-10)45 via RStudio Version 0.98.50746 . The mixed-effects modelling were done using lmer47 (link). The visualization of regression results was done using visreg44 , and the significance of interactions terms and interaction means were determined using Phia package43 . Unless otherwise stated all p-values have been multiple test corrected according to Holm’s method48 . For simulation experiments normal distributions were obtained from rnorm and skewed distribution were obtained using skew normal distribution methods, rsn, from the R package sn49 .
Breen E.J., Tan W, & Khan A. (2016). The Statistical Value of Raw Fluorescence Signal in Luminex xMAP Based Multiplex Immunoassays. Scientific Reports, 6, 26996.
Publication 2016
Biological Assay BLOOD CD163 protein, human Chitinases Chronic Obstructive Airway Disease Diabetes Mellitus, Non-Insulin-Dependent Fluorescence Freezing Homo sapiens IL6R protein, human IL6ST protein, human IL10 protein, human IL19 protein, human IL20 protein, human IL22 protein, human IL32 protein, human Infectious Mononucleosis Inflammation Interferon Type II Interleukin-11 Interleukin-12 Interleukin-12 Subunit p40 Interleukin-27 interleukin-34, human Interstitial Collagenase Light Matrix Metalloproteinase 3 MMP2 protein, human Multiple Myeloma Patients Plasma Psoriasis Rheumatoid Arthritis Safety Saliva Serum TNFRSF1A protein, human TNFRSF1B protein, human TNFSF12 protein, human TNFSF13B protein, human Urine
2
Genomic Analysis of Hematological Malignancies
Cited 19 times
In this study, we analyzed the single-nucleotide variant (SNV) catalog from four WGS cohorts: 143 CLLs (EGAS00000000092)52 (link),53 (link), 30 MMs (EGAD00001003309)3 ,9 (link), 50 AMLs (phs000178.v1.p1)59 (link), and two unpublished t-AML (EGAD00001005028). These last two cases were sequenced after written informed consent was obtained at the Wellcome Sanger Institute using the X10 Illumina platform. FASTQ files were aligned to the reference genome using BWAmem, and deduplicated aligned BAM files were analyzed using the following tools: ASCAT for copy number changes, BRASS for structural variations (large inversions and deletions, translocations, internal tandem duplication), Caveman and Pindel for Single-Nucleotide Variants (SNVs) and small insertion-deletions20 (link),66 (link)–68 (link), respectively. The characterization of the main clinical and genomic features of MM and CLL series is summarized in Supplementary Table 1 and Supplementary Data 2, respectively. Kataegis was defined as a cluster of 6 or more consecutive mutations with an average intermutation distance of less than or equal to 1 Kb20 (link).
The study involved the use of human samples, which were collected after written informed consent was obtained (Wellcome Trust Sanger Institute protocol number 15/046 for the myeloma samples, Fondazione IRCCS Istituto Nazionale dei Tumori code 127/16 for the t-AML samples).
Maura F., Degasperi A., Nadeu F., Leongamornlert D., Davies H., Moore L., Royo R., Ziccheddu B., Puente X.S., Avet-Loiseau H., Campbell P.J., Nik-Zainal S., Campo E., Munshi N, & Bolli N. (2019). A practical guide for mutational signature analysis in hematological malignancies. Nature Communications, 10, 2969.
Publication 2019
brass Gene Deletion Genome Homo sapiens Inversion, Chromosome Multiple Myeloma Mutation Nucleotides Translocation, Chromosomal
3
Evaluating PRO-CTCAE in Oncology Patients
Cited 19 times
Adult patients initiating or undergoing outpatient chemotherapy, radiation, or both at one of nine U.S. cancer centers or community oncology practices were approached in clinical waiting areas and invited to participate in this study. Participating sites with number of patients enrolled included Dana-Farber Cancer Institute, Boston, MA (N=40); Hartford Hospital-Helen and Harry Gray Cancer Center, Hartford, CT (N=104); Helen F. Graham Cancer Center & Research Institute at Christiana Care Health System, Newark, DE (N=105); Mayo Clinic, Rochester, MN (N=9); Memorial Sloan Kettering Cancer Center, New York, NY (N=280); Our Lady of the Lake and Mary Bird Perkins Cancer Center, Baton Rouge, LA (N=133); Gibbs Cancer Center, Spartanburg, SC (N=113); St. Joseph Hospital of Orange, Orange, CA (N=104); and University of Texas M. D. Anderson Cancer Center, Houston, TX (N=52).
Eligibility criteria required that all participants be able to read and comprehend English, be without clinically significant cognitive impairment based on site investigator judgment, have a cancer diagnosis, and be actively undergoing cancer treatment or be initiating treatment in the next 7 days. Patients with any cancer type were eligible, but an accrual strategy was used to enrich for specific cancer types in order to facilitate planned comparisons between groups based on cancer type in the validity analysis, including breast; aerodigestive tract (head/neck and esophageal cancer); genitourinary (prostate and bladder); lung; colorectal; and lymphoma/myeloma. An enrichment strategy was also employed to ensure that a minimum of 15% of participants had impaired performance status (PS) defined as Eastern Cooperative Oncology Group (ECOG) PS ≥2.
Study sites were selected to encompass geographic, racial/ethnic, economic, and educational diversity reflective of the U.S. population with the understanding that the requirement to be English speaking would limit the enrollment of Hispanic patients (a separate study evaluating the Spanish language version of the PRO-CTCAE has been conducted18 ). Race/ethnicity was self-reported by patients.
Institutional review board approval was obtained at all sites and at the NCI, and all patients completed written informed consent. The trial was registered on ClincialTrials.gov (NCT02158637). Each participant received a $20 gift card or parking voucher.
Dueck A.C., Mendoza T.R., Mitchell S.A., Reeve B.B., Castro K.M., Rogak L.J., Atkinson T.M., Bennett A.V., Denicoff A.M., O'Mara A.M., Li Y., Clauser S.B., Bryant D.M., Bearden J.D., Gillis T.A., Harness J.K., Siegel R.D., Paul D.B., Cleeland C.S., Schrag D., Sloan J.A., Abernethy A.P., Bruner D.W., Minasian L.M, & Basch E. (2015). Validity and Reliability of the U.S. National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). JAMA oncology, 1(8), 1051-1059.
Publication 2015
Adult Aves Breast Diagnosis Disorders, Cognitive Eligibility Determination Esophageal Cancer Ethics Committees, Research Ethnicity Head Hispanic or Latino Hispanics Lung Lymphoma Malignant Neoplasms Multiple Myeloma Neck Neoplasms Outpatients Patients Pharmacotherapy Prostate Radiotherapy System, Genitourinary Urinary Bladder
4
Parallel Evaluation of NGF MRD in Multiple Myeloma
Cited 17 times
Overall, 228 MM diagnostic (n=66) and follow-up (n=162) BM samples (n=110 in VGPR or CR/sCR) were evaluated in parallel with the NGF MRD approach vs local routine flow-MRD methods (that is, conventional 8-color flow-MRD technique).24 (link) Detailed description of these BM samples, related patient clinical data, disease status and time points at evaluation is provided in Supplementary Tables 1, 3 and 4. Briefly, conventional flow-MRD was based on staining of 300 μl of whole BM with a single 8-color antibody combination (CD45-PacB CD138-OC515 CD38-FITC CD56-PE CD27-PerCPCy5.5 CD19-PECy7 CD117-APC CD81-APCH7), as previously described.24 (link) In turn, for the NGF approach a median volume of 1.5±1.3 ml (range: 0.1–5.3 ml) was employed adding up to a median total sample volume of 1.8 ml (maximum of 5.6 ml). PC populations that coexisted in individual BM samples were identified based on a combination of the CD38, CD138, CD45 PC-associated markers and light scatter characteristics, the presence vs absence of myeloma-associated phenotypes, plus CyIg light chain restriction in case of NGF, as described elsewhere.48 (link) According to consensus recommendations,42 (link) the limit of quantitation and the LOD of the NGF MRD method was calculated at <5 × 10−6 and <2 × 10−6 aPC, based on the identification of ⩾50 and ⩾20 aPC among 107 events, respectively. More detailed information about instrument conditions, data acquisition and analysis, and the specific reagents used in the present study is provided as Supplementary Material.
Automatic identification and enumeration of aPC was performed in 110 MM BM follow-up (VGPR or CR/sCR) samples using the automatic gating function of the Infinicyt software and previously described procedures,49 , 50 and the results were compared against the conventional expert-guided PC-identification/gating approach. For automatic gating, a database consisting of a subset of 14 normal BM samples stained with Version 5 of the antibody panel was constructed and used.50 In a subset of 31 MM follow-up BM samples with low MRD levels (for example, ⩽10−4) in which enough DNA was available, MRD was also evaluated by NGS. For this purpose, patient-specific VDJH rearrangements were amplified and directly sequenced from DNA extracted from diagnostic samples using the DNAzol reagent (MRC, Cincinnati, OH, USA) and IGHV family-specific primers that covered framework regions 1 (FR1) and FR2, plus a JH consensus primer, as described elsewhere.26 (link), 32 (link)VDJH rearrangements identified at diagnosis were used as MRD-targeted sequences for subsequent follow-up samples. Follow-up DNA samples were amplified using the LymphoTrack IGH Assay (InVivoScribe Technologies, San Diego, CA, USA) and sequenced in an Illumina MiSeq platform (Illumina, San Diego, CA, USA). To all reactions, a known amount of DNA from the MWCL-1 cell line was added as reference control for cell enumeration. The Fastq files generated were analyzed with the LymphoTrack/MiSeq Software (InVivoScribe/Illumina). The number of MRD cells was calculated from the number of reads for the diagnostic VDJH target rearrangements and the number of reads of the reference rearrangement; percentage MRD was calculated upon dividing the number (× 100) of MRD cells by the total number of cells in the reaction.
Flores-Montero J., Sanoja-Flores L., Paiva B., Puig N., García-Sánchez O., Böttcher S., van der Velden V.H., Pérez-Morán J.J., Vidriales M.B., García-Sanz R., Jimenez C., González M., Martínez-López J., Corral-Mateos A., Grigore G.E., Fluxá R., Pontes R., Caetano J., Sedek L., del Cañizo M.C., Bladé J., Lahuerta J.J., Aguilar C., Bárez A., García-Mateo A., Labrador J., Leoz P., Aguilera-Sanz C., San-Miguel J., Mateos M.V., Durie B., van Dongen J.J, & Orfao A. (2017). Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma. Leukemia, 31(10), 2094-2103.
Publication 2017
Biological Assay Cell Lines Cells Diagnosis DNA, A-Form Fluorescein-5-isothiocyanate Gene Rearrangement Immunoglobulins Light Multiple Myeloma Oligonucleotide Primers Patients Phenotype Population Group SDC1 protein, human
5
Treating Skeletal Metastases: A Retrospective Study
Cited 17 times
Between January 2005 and January 2008, a total of 958 patients were prospectively registered at the time of detection of symptomatic bone metastasis. Among them, we excluded those who had already undergone treatment at other institutes, or had not been treated at our institution. Consequently, our study group comprised 808 consecutive patients who had undergone surgical and/or nonsurgical treatment, or palliative care for skeletal metastases at our institute. The patients were prospectively followed and the last follow-up evaluation was performed in January 2012. There were 441 male and 367 female patients with a median age of 64 (range, 8–94) years.
Of the 808 patients, 779 (96%) were followed up for a minimum of 24 months, unless death supervened, during which time 29 were lost to follow-up. These 29 patients were treated as “censored observations.” Two deaths from causes other than malignancy were also treated as censored observations. The median follow-up periods were 6.4 (range, 0.25–77) months for patients dying from malignant disease, and 53.9 (range, 1–82) months for survivors. Multiple myeloma requiring orthopedic care or radiotherapy was treated as a skeletal metastasis 3 (link),5 (link),8 (link),12 .
Lung carcinoma was the most common primary lesion (26%) in the patient population. Other lesions were carcinoma of the breast (17%), colon and rectum (9%), stomach (6%), prostate (5%), and liver (5%). The primary lesion was not found in 16 patients despite thorough investigation (Table 1).
Katagiri H., Okada R., Takagi T., Takahashi M., Murata H., Harada H., Nishimura T., Asakura H, & Ogawa H. (2014). New prognostic factors and scoring system for patients with skeletal metastasis. Cancer Medicine, 3(5), 1359-1367.
Publication 2014
Breast Carcinoma Colon Liver Lung Cancer Males Malignant Neoplasms Multiple Myeloma Neoplasm Metastasis Operative Surgical Procedures Palliative Care Patients Prostate Radiotherapy Rectum Skeleton Stomach Survivors Temporal Bone Woman

Most recents protocols related to «Multiple Myeloma»

1
Tucaresol Combination Therapy Evaluation
Not available on PMC !

Example 1

1) Tucaresol

Tucaresol (0-1200 μM) is exposed for 72 hours to a panel of human liquid, hematological, and solid tumors such as multiple myeloma, leukemia, colorectal, non-small cell lung cancer (squamous and adenocarcinoma), hepatocellular, renal, pancreatic and breast cancer cell lines, and human non-tumor such as HUVEC, PBMC, skin fibroblast cells lines. Tucaresol is studied either alone or in combination with standard-of-care agents (1-100 μM). All cell lines are grown in standard serum-containing media with an exposure time of 24-144 hours. Cell viability is measured using, for example, the Cell TiterGlo® Viability Assay. The potency (IC50) and efficacy (% cell kill) are determined from the percent cell growth of the vehicle control.

2) Tucaresol Plus PD-1 Antibody

Tucaresol (0-1200 μM) in the presence of a PD-1 antibody is exposed for 72 hours to a panel of human liquid, hematological, and solid tumor such as multiple myeloma, leukemia, colorectal, non-small cell lung cancer (squamous and adenocarcinoma), hepatocellular, renal, pancreatic and breast cancer cell lines, and human non-tumor such as HUVEC, PBMC, skin fibroblast cells lines, and the viability of the cell lines are measured as described above. The viability of the cell lines in the presence of tucaresol plus PD-1 antibody is compared to the viability of the cell lines in the presence of a CTLA-4 antibody plus the PD-1 antibody or PD-1 antibody alone.

3) CTLA-4 Antibody Plus PD-1 Antibody

CTLA-4 antibody in the presence of a PD-1 antibody is exposed for 72 hours to a panel of human liquid, hematological, and solid tumor such as multiple myeloma, leukemia, colorectal, non-small cell lung cancer (squamous and adenocarcinoma), hepatocellular, renal, pancreatic and breast cancer cell lines, and human non-tumor such as HUVEC, PBMC, skin fibroblast cells lines, and the viability of the cell lines are measured as described above.

4) Tucaresol Plus Plinabulin

Tucaresol (0-1200 μM) in the presence of Plinabulin is exposed for 72 hours to a panel of human liquid, hematological, and solid tumor such as multiple myeloma, leukemia, colorectal, non-small cell lung cancer (squamous and adenocarcinoma), hepatocellular, renal, pancreatic and breast cancer cell lines, and human non-tumor such as HUVEC, PBMC, skin fibroblast cells lines, and the viability of the cell lines are measured as described above.

The viability of the cell lines in the presence of tucaresol, tucaresol plus PD-1 antibody, CTLA-4 antibody plus the PD-1 antibody, and tucaresol plus plinabulin are compared.

US11857522B2. Compositions containing tucaresol or its analogs (2024-01-02). BeyondSpring Pharmaceuticals, Inc. [US]. Inventors: Ramon Mohanlal [US], Lan Huang [US], George Kenneth Lloyd [US].
Patent 2024
Adenocarcinoma Biological Assay Cell Lines Cells Cell Survival Cytotoxic T-Lymphocyte Antigen 4 Fibroblasts Homo sapiens Immunoglobulins Kidney Leukemia MCF-7 Cells Multiple Myeloma Neoplasms Non-Small Cell Lung Carcinoma Pancreas plinabulin Serum Skin tucaresol
2
Cellular Internalization of Modified miRNAs
Not available on PMC !

Example 2

Once miRNAs were modified by elongation and fluorescently marked to enable intracellular tracking of modified miRNAs, Applicants assessed cellular internalization of PS-modified miRNAs by flow cytometry including PO-modified miRNA as negative non-internalizing controls. Human multiple myeloma cells MM.1 S were incubated either for 30 min or for 48 hrs with modified miRNA as indicated and analyzed by flow cytometry to assess cellular load of cells with modified miRNA. For modified let7a-3p miRNA (FIGS. 2A and 2B) and modified let7a-5p miRNA (FIGS. 4A and 4B), 10 μg/ml was used for both 30 min and 48 hr incubation. For miR17-3p miRNA (FIGS. 6A and 6B), modified miR17-5p miRNA (FIGS. 8A and 8B) and modified miR218-5p miRNA (FIGS. 10A and 10B), 20 μg/ml was used for 30 min incubation and 10 μg/ml was used for 48 hr incubation, respectively.

US11857633B2. Phosphorothioate-conjugated miRNAs and methods of using the same (2024-01-02). City of Hope [US]. Inventors: Andreas Herrmann [US], Hua Yu [US].
Patent 2024
Cells DNA, Single-Stranded Figs Flow Cytometry Homo sapiens MicroRNAs Multiple Myeloma Oligonucleotides Protoplasm
3
Inhibition of STAT3 Signaling in Multiple Myeloma
Not available on PMC !

Example 3

Human multiple myeloma cancer cells are known to undergo increased cell division through IL-6-triggered STAT3 signaling. Numerous studies have shown that let7a-3p miRNA (SEQ ID NO:1), let7a-5p miRNA (SEQ ID NO:2), miR17-3p miRNA (SEQ ID NO:3), miR17-5p miRNA (SEQ ID NO:4), or miR218-5p miRNA (SEQ ID NO:5) inhibits the activity of transcription factor Signal Transducer and Activator of Transcription 3 (STAT3). Human multiple myeloma cells MM.1S were incubated for 48 hrs daily with 10 μg/ml modified miRNA as indicated and expression of the STAT3 target genes was analyzed by RT-PCR. As shown in FIGS. 2C, 4C, 6C, 8C and 10C, incubation with PS-modified let7a-3p miRNA (SEQ ID NO:1), let7a-5p miRNA (SEQ ID NO:2), miR17-3p miRNA (SEQ ID NO:3), miR17-5p miRNA (SEQ ID NO:4), or miR218-5p miRNA (SEQ ID NO:5) inhibited expression of STAT3 target genes, for example, oncogenic Bcl-xL and/or IL-6 genes.

US11857633B2. Phosphorothioate-conjugated miRNAs and methods of using the same (2024-01-02). City of Hope [US]. Inventors: Andreas Herrmann [US], Hua Yu [US].
Patent 2024
Cells Division, Cell DNA, Single-Stranded Figs Gene Expression Genes Homo sapiens Malignant Neoplasms MicroRNAs Multiple Myeloma Oligonucleotides Oncogenes Reverse Transcriptase Polymerase Chain Reaction STAT3 Protein Transcription Factor
4
Evaluating Tucaresol and Checkpoint Inhibitors in Xenograft Models
Not available on PMC !

Example 7

Five groups including tucaresol, tucaresol plus PD-1 or PD-L1 antibody, tucaresol plus CTLA-4 antibody, CTLA-4 antibody plus PD-1 or PD-L1 antibody, and tucaresol plus plinabulin are tested to determine their effect in an animal xenograft model.

The combined treatment with tucaresol and the checkpoint inhibitor(s) is tested in comparison with the treatment with tucaresol alone, the treatment with checkpoint inhibitor alone, or combination of checkpoint inhibitors. The tests are performed using seven to ten-week old athymic (nu/nu) mice that were injected subcutaneously with human tumor cell lines (of either solid or liquid tumor origin, for example of breast, lung, colon, brain, liver, leukemia, myeloma, lymphoma, sarcoma, pancreatic or renal origin). Six to ten testing groups are prepared, and each group includes 10 mice.

Each treatment starts at tumor size between 40-150 mm3 and continues until Day 24-56, when the animals are necropsied. To determine the efficacy of each treatment, the following data are collected: mortality; the body weight of the mice assessed twice weekly both prior to treatments; the rate of tumor growth as determined by the tumor size measurement (twice every week); the tumor growth index; overall survival rate; the tumor weight at necropsy; and the time required to increase tumor size 10 fold.

US11857522B2. Compositions containing tucaresol or its analogs (2024-01-02). BeyondSpring Pharmaceuticals, Inc. [US]. Inventors: Ramon Mohanlal [US], Lan Huang [US], George Kenneth Lloyd [US].
Patent 2024
Animal Model Animals Autopsy Body Weight Brain Breast CD274 protein, human Cell Cycle Checkpoints Cell Line, Tumor Colon Combined Modality Therapy CTLA4 protein, human Genes, Neoplasm GZMB protein, human Heterografts Homo sapiens Immunoglobulins inhibitors Kidney Leukemia Liver Lung Lymphoma Mice, Nude Multiple Myeloma Mus Neoplasms Pancreas plinabulin Sarcoma Thymic aplasia tucaresol
5
Let7a-5p miRNA Inhibits STAT3 Signaling in Multiple Myeloma
Not available on PMC !

Example 6

Human multiple myeloma cancer cells are known to undergo increased cell division through IL-6-triggered STAT3 signaling. Numerous studies have shown that let7a-5p miRNA (SEQ ID NO:2) inhibits the activity of Signal Transducer and Activator of Transcription 3 (STAT3). Human multiple myeloma cells MM.1S were incubated for 48 hrs daily with 10 μg/ml polymer-modified let7a-5p miRNA as indicated and expression of the STAT3 target gene, oncogenic Bcl-xL gene, was analyzed by RT-PCR. As shown in FIG. 12B, incubation with PS polymer-modified let7a-5p miRNA inhibited expression of Bcl-xL gene.

US11857633B2. Phosphorothioate-conjugated miRNAs and methods of using the same (2024-01-02). City of Hope [US]. Inventors: Andreas Herrmann [US], Hua Yu [US].
Patent 2024
Cells Division, Cell Gene Expression Genes Homo sapiens Malignant Neoplasms MicroRNAs Multiple Myeloma Oncogenes Polymers Reverse Transcriptase Polymerase Chain Reaction STAT3 Protein Sugar Phosphates Vertebral Column

Top products related to «Multiple Myeloma»

1
Fetal bovine serum (fbs) by Thermo Fisher Scientific
Sourced in United States, China, United Kingdom, Germany, Australia, Japan, Canada, Italy, France, Switzerland, New Zealand, Brazil, Belgium, India, Spain, Israel, Austria, Poland, Ireland, Sweden, Macao, Netherlands, Denmark, Cameroon, Singapore, Portugal, Argentina, Holy See (Vatican City State), Morocco, Uruguay, Mexico, Thailand, Sao Tome and Principe, Hungary, Panama, Hong Kong, Norway, United Arab Emirates, Czechia, Russian Federation, Chile, Moldova, Republic of, Gabon, Palestine, State of, Saudi Arabia, Senegal
Fetal Bovine Serum (FBS) is a cell culture supplement derived from the blood of bovine fetuses. FBS provides a source of proteins, growth factors, and other components that support the growth and maintenance of various cell types in in vitro cell culture applications.
2
Rpmi8226 by American Type Culture Collection
Sourced in United States, Germany, France
RPMI8226 is a human myeloma cell line derived from the peripheral blood of a patient with multiple myeloma. The cell line is widely used in research for studying multiple myeloma and related blood disorders.
3
Rpmi 1640 medium by Thermo Fisher Scientific
Sourced in United States, China, Germany, United Kingdom, Japan, France, Canada, Australia, Italy, Switzerland, Belgium, New Zealand, Spain, Israel, Sweden, Denmark, Macao, Brazil, Ireland, India, Austria, Netherlands, Holy See (Vatican City State), Poland, Norway, Cameroon, Hong Kong, Morocco, Singapore, Thailand, Argentina, Taiwan, Province of China, Palestine, State of, Finland, Colombia, United Arab Emirates
RPMI 1640 medium is a commonly used cell culture medium developed at Roswell Park Memorial Institute. It is a balanced salt solution that provides essential nutrients, vitamins, and amino acids to support the growth and maintenance of a variety of cell types in vitro.
4
Rpmi 1640 by Thermo Fisher Scientific
Sourced in United States, China, United Kingdom, Germany, France, Canada, Japan, Australia, Italy, Switzerland, Belgium, New Zealand, Austria, Netherlands, Israel, Sweden, Denmark, India, Ireland, Spain, Brazil, Norway, Argentina, Macao, Poland, Holy See (Vatican City State), Mexico, Hong Kong, Portugal, Cameroon
RPMI 1640 is a common cell culture medium used for the in vitro cultivation of a variety of cells, including human and animal cells. It provides a balanced salt solution and a source of essential nutrients and growth factors to support cell growth and proliferation.
5
Streptomycin by Thermo Fisher Scientific
Sourced in United States, United Kingdom, Germany, China, France, Canada, Australia, Japan, Switzerland, Italy, Belgium, Israel, Austria, Spain, Netherlands, Poland, Brazil, Denmark, Argentina, Sweden, New Zealand, Ireland, India, Gabon, Macao, Portugal, Czechia, Singapore, Norway, Thailand, Uruguay, Moldova, Republic of, Finland, Panama
Streptomycin is a broad-spectrum antibiotic used in laboratory settings. It functions as a protein synthesis inhibitor, targeting the 30S subunit of bacterial ribosomes, which plays a crucial role in the translation of genetic information into proteins. Streptomycin is commonly used in microbiological research and applications that require selective inhibition of bacterial growth.
6
Penicillin by Thermo Fisher Scientific
Sourced in United States, United Kingdom, Germany, China, France, Canada, Japan, Australia, Switzerland, Italy, Israel, Belgium, Austria, Spain, Brazil, Netherlands, Gabon, Denmark, Poland, Ireland, New Zealand, Sweden, Argentina, India, Macao, Uruguay, Portugal, Holy See (Vatican City State), Czechia, Singapore, Panama, Thailand, Moldova, Republic of, Finland, Morocco
Penicillin is a type of antibiotic used in laboratory settings. It is a broad-spectrum antimicrobial agent effective against a variety of bacteria. Penicillin functions by disrupting the bacterial cell wall, leading to cell death.
7
Mm 1s by American Type Culture Collection
Sourced in United States, Germany
The MM.1S is a cell culture incubator designed for maintaining optimal conditions for cell growth and proliferation. It provides a controlled environment with precise temperature, humidity, and gas composition regulation. The MM.1S is a core laboratory equipment piece suitable for a variety of cell culture applications.
8
Complete freund s adjuvant by Merck Group
Sourced in United States, China, Germany, United Kingdom, India, France, Japan, Poland, Sao Tome and Principe, Australia, Macao, Canada, Spain, Denmark, Israel, Sweden
Complete Freund's adjuvant is a laboratory reagent used to enhance the immune response in laboratory animals during the production of antibodies. It contains inactivated and dried mycobacteria suspended in a mineral oil emulsion. The mycobacteria component serves to stimulate the animal's immune system, leading to a stronger and more sustained antibody response to the antigen of interest.
9
Penicillin streptomycin by Thermo Fisher Scientific
Sourced in United States, Germany, United Kingdom, China, Canada, France, Japan, Australia, Switzerland, Israel, Italy, Belgium, Austria, Spain, Gabon, Ireland, New Zealand, Sweden, Netherlands, Denmark, Brazil, Macao, India, Singapore, Poland, Argentina, Cameroon, Uruguay, Morocco, Panama, Colombia, Holy See (Vatican City State), Hungary, Norway, Portugal, Mexico, Thailand, Palestine, State of, Finland, Moldova, Republic of, Jamaica, Czechia
Penicillin/streptomycin is a commonly used antibiotic solution for cell culture applications. It contains a combination of penicillin and streptomycin, which are broad-spectrum antibiotics that inhibit the growth of both Gram-positive and Gram-negative bacteria.
10
L glutamine by Thermo Fisher Scientific
Sourced in United States, United Kingdom, Germany, France, Canada, Switzerland, Italy, Australia, Belgium, China, Japan, Austria, Spain, Brazil, Israel, Sweden, Ireland, Netherlands, Gabon, Macao, New Zealand, Holy See (Vatican City State), Portugal, Poland, Argentina, Colombia, India, Denmark, Singapore, Panama, Finland, Cameroon
L-glutamine is an amino acid that is commonly used as a dietary supplement and in cell culture media. It serves as a source of nitrogen and supports cellular growth and metabolism.

More about "Multiple Myeloma"

Multiple myeloma (MM) is a type of blood cancer that affects plasma cells, a specialized form of white blood cells.
It is characterized by the uncontrolled growth and accumulation of abnormal plasma cells in the bone marrow, leading to a variety of complications such as bone pain, fractures, and kidney problems.
The RPMI8226 cell line is a widely used in vitro model for MM research, derived from the malignant plasma cells of a patient with MM.
These cells are typically cultured in RPMI 1640 medium, often supplemented with FBS (fetal bovine serum), L-glutamine, and antibiotics like penicillin and streptomycin, to provide the necessary nutrients and growth factors.
Another commonly used MM cell line is MM.1S, which exhibits similar characteristics to the disease.
Complete Freund's adjuvant has been utilized in some MM studies to induce an immune response and better understand the disease pathogenesis.
PubCompare.ai is an AI-driven platform that can help researchers optimize their MM research by providing powerful comparison tools to locate the best protocols from literature, preprints, and patents.
This can aid in the identification of the most effective treatments and the discovery of future protocol optimization strategies for this complex and challenging disease.